GP
FOLD

GLG Partners’s Amicus Therapeutics FOLD Stock Holding History

GLG Partners’s Portfolio FOLD Stock Details FOLD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q1 		– Sell
-40,693
Closed -$395K – 442
2015
Q4 		$395K Sell
40,693
-40,586
-50% -$366K 0.01% 385
2015
Q3 		$1.14M Buy
81,279
+26,921
+50% +$422K 0.03% 340
2015
Q2 		$769K Buy
+54,358
New +$654K 0.02% 376
2013
Q3 		– Sell
-125,202
Closed -$292K – 203
2013
Q2 		$292K Buy
+125,202
New +$385K 0.01% 262

Other funds holding FOLD

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
SAM
Sectoral Asset Management Montreal, Quebec, Canada $121M AUM 73.47% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
JHIU
Janus Henderson Investors US Denver, Colorado $122B AUM 18.26% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

GLG Partners's FOLD Position: Q1 2016 in Review

GLG Partners sold out of Amicus Therapeutics (FOLD) in Q1 2016, closing a stake of 40,693 shares — an estimated $395K sold.

GLG Partners first reported a position in FOLD in Q2 2013 and held it in 4 quarters. The position peaked at $1.14M in Q3 2015. 128 funds tracked by Wall St. Rank hold FOLD as of Q1 2016.

  • GLG Partners reported no remaining Amicus Therapeutics position as of Q1 2016 after selling out during the quarter.
  • GLG Partners sold 40,693 Amicus Therapeutics shares in Q1 2016, an estimated $395K.
  • GLG Partners first reported a position in Amicus Therapeutics in Q2 2013 and held it in 4 quarters.
  • GLG Partners's Amicus Therapeutics position peaked at $1.14M in Q3 2015.
  • 128 funds tracked by Wall St. Rank held Amicus Therapeutics as of Q1 2016.

Based on GLG Partners's 13F filing for Q1 2016, filed 16 May 2016.